Predictability of Idiosyncratic Drug Toxicity Risk for Carboxylic Acid-Containing Drugs Based on the Chemical Stability of Acyl Glucuronide

被引:108
作者
Sawamura, Ryoko [1 ]
Okudaira, Noriko [1 ]
Watanabe, Kengo [1 ]
Murai, Takahiro [1 ]
Kobayashi, Yoshimasa [1 ]
Tachibana, Masaya [2 ]
Ohnuki, Takashi [3 ]
Masuda, Kayoko [3 ]
Honma, Hidehito [4 ]
Kurihara, Atsushi [1 ]
Okazaki, Osamu [1 ]
机构
[1] Daiichi Sankyo Co Ltd, Drug Metab & Pharmacokinet Res Labs, Tokyo, Japan
[2] Daiichi Sankyo Co Ltd, Translat Med & Clin Pharmacol Dept, Tokyo, Japan
[3] Daiichi Sankyo Co Ltd, Lead Discovery & Optimizat Res Labs, Tokyo, Japan
[4] Daiichi Sankyo RD Associe Co Ltd, Res Dept 1, Tokyo, Japan
关键词
HUMAN SERUM-ALBUMIN; IN-VITRO; COVALENT BINDING; METABOLIC-ACTIVATION; REACTIVITY; MECHANISM; VIVO; DEGRADATION; ZOMEPIRAC; PROTEINS;
D O I
10.1124/dmd.110.034173
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Acyl glucuronides (AGs) formed from carboxylic acid-containing drugs have been considered to be a cause of idiosyncratic drug toxicity (IDT). Chemical stability of AGs is supposed to relate to their reactivity. In this study, the half-lives of 21 AGs of carboxylic drugs in potassium phosphate buffer (KPB), human serum albumin (HSA) solution, and human fresh plasma were analyzed in relation to the IDT risk derived from these drugs. The carboxylic drugs were classified into three safety categories of "safe," "warning," and "withdrawn" in terms of their IDT risk. As for the results, the half-lives of AGs in KPB correlated with the IDT risk better than those in HSA solution or in human fresh plasma with regard to the separation of the safe drugs from the warning drugs or the withdrawn drugs. In KPB, whereas the half-lives in the safe category were 7.2 h or longer, those in the withdrawn category were 1.7 h or shorter. The classification value of the half-life in KPB, which separated the safe drugs from the withdrawn drugs was calculated to be 3.6 h by regression analysis. In conclusion, this is the first report that clearly shows the relationship between the IDT risk and chemical stability of AGs in several in vitro systems. The KPB system was considered to be the best for evaluating the stability of AGs, and the classification value of the half-life in KPB serves as a useful key predictor for the IDT risk.
引用
收藏
页码:1857 / 1864
页数:8
相关论文
共 27 条
[1]   Structure-Activity Relationships for Degradation Reaction of 1-β-O-Acyl Glucuronides: Kinetic Description and Prediction of Intrinsic Electrophilic Reactivity under Physiological Conditions [J].
Baba, Akiko ;
Yoshioka, Tadao .
CHEMICAL RESEARCH IN TOXICOLOGY, 2009, 22 (01) :158-172
[2]   Acyl glucuronide reactivity in perspective: biological consequences [J].
Bailey, MJ ;
Dickinson, RG .
CHEMICO-BIOLOGICAL INTERACTIONS, 2003, 145 (02) :117-137
[3]   Limitations of hepatocytes and liver homogenates in modelling in vivo formation of acyl glucuronide-derived drug-protein adducts [J].
Bailey, MJ ;
Dickinson, RG .
JOURNAL OF PHARMACOLOGICAL AND TOXICOLOGICAL METHODS, 1999, 41 (01) :27-32
[4]   Future of toxicology-metabolic activation and drug design: Challenges and opportunities in chemical toxicology [J].
Baillie, Thomas A. .
CHEMICAL RESEARCH IN TOXICOLOGY, 2006, 19 (07) :889-893
[5]   PREDICTABILITY OF THE COVALENT BINDING OF ACIDIC DRUGS IN MAN [J].
BENET, LZ ;
SPAHNLANGGUTH, H ;
IWAKAWA, S ;
VOLLAND, C ;
MIZUMA, T ;
MAYER, S ;
MUTSCHLER, E ;
LIN, ET .
LIFE SCIENCES, 1993, 53 (08) :PL141-PL146
[6]  
Boelsterli Urs A, 2002, Curr Drug Metab, V3, P439, DOI 10.2174/1389200023337315
[7]   Development of an in vitro screening model for the biosynthesis of acyl glucuronide metabolites and the assessment of their reactivity toward human serum albumin [J].
Bolze, S ;
Bromet, N ;
Gay-Feutry, C ;
Massiere, F ;
Boulieu, R ;
Hulot, T .
DRUG METABOLISM AND DISPOSITION, 2002, 30 (04) :404-413
[8]  
CASTILLO M, 1995, DRUG METAB DISPOS, V23, P566
[9]   STUDIES ON THE REACTIVITY OF ACYL GLUCURONIDES .2. INTERACTION OF DIFLUNISAL ACYL GLUCURONIDE AND ITS ISOMERS WITH HUMAN SERUM-ALBUMIN INVITRO [J].
DICKINSON, RG ;
KING, AR .
BIOCHEMICAL PHARMACOLOGY, 1991, 42 (12) :2301-2306
[10]  
Georges H, 2000, CHIRALITY, V12, P53